Yeah, I agree with Sector about CYP being in a position to somewhat learn and take advantage from MSB's mistakes.
I do think it's a mistake to say msb are aGvHD only, they have allready announced intent to try adults, and I think they would possibly expand directly into GvHD either off label, or once they have found a link between pre-treatment biomarkers and efficacy , they could become first line therapy instead of steroids for the people that display the correct pre-treatment biomarkers.
I do think that will happen before CYP are even finished phase 3, maybe not before they are taken over ( if that happens )
MSB-CYP- Can we compare them?, page-23
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
-0.220(12.4%) |
Mkt cap ! $1.838B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $14.23M | 8.823M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 14579 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 35679 | 5 |
View Market Depth
| Last trade - 15.52pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |